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Abstract 
 Cervical cancer is the fourth most frequent cancer in women around the world. In the 
Central American region, it is a leading cause of mortality for young women due to inadequate 
preventive and screening measures. The disease is slow-growing and caused by the human 
papillomavirus, which is transmitted via sexual contact. The HPV vaccination was created in 
order to prevent the disease, and there are a variety of quality screening methods to quickly 
identify progression. The most common screening methods include the Papanicolaou (Pap) test 
and visualization by acetic acid (VIA). While frequent screening is common in developed 
countries, rates are much lower in Central American countries primarily due to financial and 
educational constraints. In order to prevent cases of cervical cancer in this region, current 
educational assistance programs should be expanded, and financial assistance must be procured. 
In terms of screening, VIA should be preferred over Pap testing in Central America due to its 
cost effectiveness and lesser training requirements.  
Introduction 
 According to the World Health Organization, cervical cancer is currently the fourth most 
frequent cancer in women across the globe.1 In comparison to other malignancies, it is a slow-
growing disease, but it can be deadly if not caught and treated in a timely manner. In 2018, there 
were approximately 311,000 women who lost their lives to the disease.2 Of these women, over 
85% resided in a less-developed or middle-income country.1-2 In the Latin American region in 
particular, cervical cancer is the most common cause of mortality due to malignant neoplasm in 
women 20-40 years of age.3 These statistics are alarming, given that with adequate screening and 
intervention methods, cervical cancer is a preventable and treatable disease.  
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 The vast majority of cervical cancer is caused by infection of the human papillomavirus 
(HPV), which is a group of non-enveloped double stranded DNA tumor viruses.4 HPV is the 
most common sexually transmitted infection (STI), and can be spread during vaginal, anal, or 
oral sex with an infected person, as well as through skin-to-skin genital contact.5 There are more 
than 100 different types of HPV, but only a select few cause disease. As the virus infects the skin 
and mucosa, some types can manifest as benign warts, whereas others will result in no symptoms 
at all. It can take weeks, months, or even years after infection for warts to develop after the initial 
infection.6 Persistent and untreated infection of types 6, 11, 16, and 18 have been identified to 
cause nearly all cervical cancers in addition to some vaginal, vulvar, and anal cancers.2,4 HPV 
was not determined to be the essentially exclusive cause until the 1980’s, and the discovery has 
allowed researchers to develop extremely effective preventative and screening recommendations 
for the public as well as providers. Similar to warts, cancers can take years to develop after an 
HPV infection. Around the world, annual cancer cases attributable to HPV number 570,000 in 
women and 60,000 in men.7 Without effective screening methods, it is nearly impossible to 
identify and treat these cancers in their earliest stages.  
 Because cervical cancer does not evolve as rapidly as some other cancers, the HPV 
infection commonly follows a fairly predictive course. The progression begins with a sexually 
transmitted HPV infection that occurs shortly after sexual activity. It is more common for a male 
partner to pass the virus to a female partner, but transmission occurs both ways. Contracting 
HPV is so common that researchers estimate that almost every person who is sexually active will 
get HPV at some point if they are not vaccinated.5 In the majority of patients, the body clears the 
virus without trouble, and there is no further disease progression. Two years after acquisition, 
90% of infections will have cleared without any intervention.2 However, if the infection consists 
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of one of the known carcinogenic strains, the abnormal cells are more likely to persist and grow. 
It is clear that action should be taken in these cases, but there can be limitations to consider.  
Depending on the region of the world, financial and geographical strains may prevent access to 
healthcare. Patients in less-developed or lower income countries are much less likely to have 
access to preventative care than if they resided in a developed country. In addition, there is a lack 
of effective programs to raise awareness about HPV and to bring in proper training in many 
Central American communities.  
Ultimately, the prevalence of global HPV transmission identifies a prominent public 
health issue that requires evaluation of screening and preventative measures. According to the 
Centers for Disease Control and Prevention (CDC) in the United States, 93% of cervical cancers 
could have been prevented with either vaccination or screening.5 This identifies a prominent gap 
in healthcare services for those in developing countries or without access to healthcare. The 
countries within Central America are in varying stages of political, economic, and social 
development and can provide insight into the challenges of implementing the ideal approaches. 
As cervical cancer is the leading cause of cancerous mortality for women in this area, it is 
imperative to find plausible ways to prevent these unnecessary deaths. This paper will explore 
the current methods in Central America, and identify opportunities to implement further action.   
Background  
Cervical Cancer Progression 
The cervix itself contains two types of cells. The endocervix is covered with glandular 
cells, and the ectocervix contains squamous cells. Both cell types come together in an area of 
metaplastic tissue between the endocervical canal and the vagina, called the transformation zone. 
Although any epithelial tissue can be infected by HPV, the transformation zone is the most 
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susceptible area for progression to precancers and cancers to occur. According to the American 
Cancer Society, 90% of cervical cancers are squamous cell carcinomas, and the majority of the 
others are adenocarcinomas from the glandular cells.8  
As previously mentioned, nearly all cervical cancers begin with a sexually-transmitted 
HPV infection. While these infections are very common, there are some factors that can put a 
patient at higher risk for STIs, including HPV. Having unprotected sex, sexual contact with 
multiple partners, and abusing drugs and alcohol all put a person at higher risk for contracting an 
STI. For HPV in particular, researchers have determined an increased risk in those who are 
immunocompromised, have had other STIs, have had many children, have been on long term 
oral contraceptives, and who engage in smoking tobacco.2,9 Following a minority of cases of 
infection, evidence of abnormal cellular morphology is detected. These findings are usually 
labeled by laboratories as “atypical squamous cells of undetermined significance (ASC-US)” or 
“low-grade squamous intraepithelial lesions (LSIL).” These abnormalities are transient, with 
over 50% naturally clearing in one year, and 90% by two years.8 
Unfortunately, cellular abnormalities can only be detected if the patient is seen in a 
healthcare setting for a pelvic exam. If the abnormal cells are not identified and treated at this 
point, there is a small chance that an unresolved low-grade lesion could progress to a high-grade 
squamous intraepithelial lesion (HSIL). In these cases, further cellular changes may continue, 
and there is potential for the abnormal morphology to fully develop into cervical cancer cells. 
Though not all high-grade lesions will become cancerous, they are considered “pre-cancerous” in 
nature. The majority of women with precancerous lesions will not display any symptoms of the 
underlying disease. Cells are most likely to progress to malignancy if the initial HPV infection 
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was high-risk, such as with HPV types 16 and 18.10 Cancer development occurs after cell 
dysplasia has been ongoing for as many as 10-15 years.  
When advanced dysplasia is allowed to advance without intervention, malignancy can 
occur. At this point, the cancer can be classified as either a squamous cell carcinoma or an 
adenocarcinoma. These early stages of cancer are when most women begin to experience 
symptoms. Patients may notice irregular vaginal bleeding or abnormal vaginal discharge. As 
with any cancer, cells can break away and travel through the bloodstream or the lymph system 
and form new tumors. Nearby lymph nodes are usually affected first, but cancer can spread to the 
vagina, bladder, rectum, and walls of the pelvis. At this stage, there is a 56% 5-year survival rate 
for women.8 In later stages, the cancer has spread to distant lymph nodes, lungs, bones, or liver. 
When metastatic disease is present, women may recognize changes in urination or defecation, 
fatigue, and weight loss.9 The 5-year survival rate drops to 17% in these cases.8 The slow-
growing nature of cervical cancer allows for many opportunities to identify and treat the lesions 
in their early stages. Women cannot rely on presenting symptoms to seek healthcare. At the time 
of symptom presentation, the cancer may already be metastatic.  
Global Recommendations for Prevention and Screening 
 Since the 1940s, the methods for screening and prevention of cervical cancer have 
developed substantially. With better technology and methodology, rates of incidence and 
mortality of cervical cancer have decreased dramatically. The first screening option created was 
the Papanicolaou (Pap) test, which involves collecting cells from the transition zone of the cervix 
and performing cytology to assess the morphology. Implementation of this method allows for 
abnormal lesions to be caught and treated before they progress to symptomatic and dangerous 
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cancers. The International Agency for Research on Cancer (IARC) found that the occurrence of 
invasive cervical cancer could be reduced by 80% or more with Pap-based screening programs.11  
The World Health Organization (WHO) recommends that women with positive cytology results 
(ASCUS, LSIL, HSIL) should either repeat cytology in a year or undergo further testing such as 
HPV testing, colposcopy, and biopsy to further characterize the lesions.12 Alternatively, women 
who test negative on cytology (Pap) should be routinely screened every three to five years.12 
While the Pap test is widely used, the results must be examined under microscopy, and there is 
potential for human error.  
 While not as widely recommended in developed countries, another screening technique 
frequently used is visual inspection by acetic acid (VIA). This is an inexpensive test in which 
acetic acid is applied directly to the cervix, allowing precancerous lesions to become visibly 
white to the naked eye.11 This method has a greater margin for error and is not as accurate in 
identifying the severity of the lesions. However, it requires little equipment and training to 
perform. 
 When HPV was determined to be the cause of nearly all cervical cancers in the 1980’s, a 
preventative vaccine as well as screening tools were developed. In 2007, the first prophylactic 
vaccine for HPV became widely available.13 In the four years following introduction, HPV 
infections in teen girls decreased by 56%.14 There are currently three options for vaccination, 
each covering various high-risk strains (quadrivalent Gardasil/Silgard, bivalent Cervarix, 
nonvalent Gardasil 9). All three vaccines cover high-risk strains 16 and 18, but none protect 
against all HPV types.13 The CDC in the United States recommends routine vaccination at 11 or 
12 years of age, as children ideally should be vaccinated before any exposure to the human 
papillomairus.14 Both males and females should be vaccinated, as both genders can transmit the 
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virus. Long-lasting immunity can be generated with 2-3 doses of the non-infectious recombinant 
vaccine.15 
The vaccine is a great option for those who are able to receive it before HPV exposure, 
but it is not therapeutic. To identify the virus after contraction has occurred, patients can undergo 
an HPV screening test. This detects the DNA of the virus itself, rather than the cellular changes 
that cytology detects. HPV testing is highly sensitive and allows for longer screening intervals – 
done every five years rather than three with cytology alone. A negative HPV test indicates the 
patient is not infected with an HPV type that is linked to cervical cancer, whereas a positive test 
indicates there is a presence of cancer-linked HPV.16 A positive test does not indicate the 
presence of cancer, but instead identifies at risk patients. HPV testing can conveniently be 
completed with the same sample obtained for cytologic testing. These tests are almost always 
completed together, deemed “co-testing” to providers and patients. The combination of the test 
results allows providers to gain a more complete understanding of HPV presence and disease 
progression. If the two tests do not correspond, further testing with colposcopy may be indicated. 
HPV tests also produce a large number of false positives, which may lead to unnecessary 
testing.11 
Prevention and screening methods are largely based on the peaks of acquisition at each 
stage of the disease. For example, the peak age group that women contract the HPV virus is in 
adolescence and early adulthood. The goal of the vaccination is to prevent infection before 
exposure occurs. Because researchers have found that the vast majority of infections are cleared 
naturally in young women, it is not recommended to screen with cytology until 21 years of age.16 
With predictive progression, the peak of HSIL lesions has been found to be around 25-30 years 
of age. In accordance with this data, it is advised that women are screened every three years with 
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cytology from ages 21-29. From ages 30-65, women may be screened with an HPV co-test (Pap 
+ HPV test).16 Because the HPV test is more sensitive to high-grade persistent lesions, it is not 
recommended for women under 30 who are more likely to have a transient infection. Studies 
have shown that the peak of cervical cancer in women is not until 45-60 years of age. This 
highlights the large window of intervention time before a high-grade lesion advances to cancer.  
Although these screening practices can be very effective, they are only useful if women 
have the ability to access and afford follow-up visits and treatment. The WHO mentions that 
successful programs are designed in order to reach the largest amount of women at risk with 
quality screening and treatment.15 
Prevention and Screening in Central America 
 Women in developing countries are disproportionately affected by cervical cancer. While 
the incidence of cervical cancer has consistently decreased in many areas, the same cannot be 
said for underdeveloped and low income nations. Technological advances that could allow 
prevention of the disease are not available to a large number of women. In the years after the 
invention of the HPV vaccine, only 3% of 10-20 year old females in less developed countries 
had received a dose.17 Throughout Central America, the incidence and mortality rates of cervical 
cancer vary considerably. In terms of cancer-related deaths, it is the leading cause in El Salvador, 
and the sixth most in Costa Rica.18  
 In terms of prevention, there are some programs focused on administering HPV 
vaccinations in some areas of Central America. In 2015, Panama was the only Central American 
country with a national vaccination schedule in place.19 Unfortunately, there are many challenges 
that must be overcome before the vaccine can become widely available. The vaccine is 
expensive, requires more than one dose, and implementation strategies are currently ineffective. 
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Additionally, the vaccine does not help women who have already been infected with HPV or 
who are beyond the recommended age range. This leaves many women in need of adequate 
screening strategies rather than prevention.  
 Pap testing is the most common method of screening around the world, but it requires an 
office visit every three years, trained providers, and microscopic analysis. Despite years of 
attempts to implement cytologic testing across Central America, rates of cancer still remain high 
in most areas.19 In well-equipped laboratories in developed countries, there is about 50% 
sensitivity in detecting high-grade lesions cervical lesions. Comparatively, sensitivity ranges 
between 22-42% in Central American countries, indicating that the majority of lesions are 
missed.20 A large number of programs in Central America are underfunded, and frequently lose 
patients to follow up. The few organized programs that do exist are located in major urban 
centers, which are inaccessible to a large portion of the population. Furthermore, a pelvic exam is 
required to collect specimens for Pap tests, and many people in this region are apprehensive due 
to cultural reasons.20 
 As previously discussed, HPV testing allows for less frequent testing, and more accurate 
screening. Costa Rica, the most politically stable and economically developed country in Central 
America, was the first in the region to begin HPV testing. The Costa Rican Ministry of Health 
conducted a large scale, long-term project called “The Guanacaste Project.” Women in this area 
had the highest cervical cancer rates in the country. After introduction of a multimethod 
screening effort including HPV testing, there was a 31% cancer incidence reduction.21 Many 
years later in 2011 the Nicaraguan government launched careHPV, which allows women the 
option to self-collect vaginal samples for HPV testing. While not as sensitive as a provider 
collected specimen, more than 80% of women agreed to the self-collected sample. In addition, 
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this collection method had a higher sensitivity for lesions in comparison to cytologic testing.20 
With the results of these studies, El Salvador, Guatemala, Honduras, and Nicaragua all began to 
introduce HPV testing to their pre-existing cytology programs. 
 Another technique commonly used in low-resource settings is visual inspection by acetic 
acid (VIA). As previously mentioned, this test is inexpensive and allows precancerous lesions to 
become visibly white to the naked eye.11 Because of the nature of the test, results are 
immediately available, preventing the need for many follow up visits. This method requires little 
training, and few resources. It is much more widely accepted across communities, and still 
produces 80% sensitivity and 92% specificity.22  
At this point in time, thousands of women in underserved parts of Central America do not 
have access to screening measures. There is a lack of organized programs and access to both 
funds and resources. Lack of services results in women seeking care when the disease has 
become invasive, and treatment options are either expensive or nonexistent. 
Methods  
 The PubMed and Google Scholar databases were utilized to complete literature searches 
related to cervical cancer screening and prevention across the world, and specifically in Central 
America. PubMed search terms included: cervical cancer prevalence, cervical cancer prevention, 
cervical cancer screening Central America, HPV vaccination, and HPV testing. Google Scholar 
search terms included: WHO HPV recommendations, cervical cancer prevention, cervical cancer 
screening Central America, HPV vaccination, and HPV testing. 
 In addition to online research, in-person interviews were conducted in Costa Rica to gain 
additional understanding of the topic. Providers and locals were asked about screening and 
prevention practices currently used, opinions and attitudes related to methods, and access to care 
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(See Appendix A). Interviews were conducted in various locations in Costa Rica, including San 
Jose, Boruca, and Longo Mai. It is important to note that interviews were completed with Costa 
Rican locals alone. Information from other Central American countries was inquired about, and 
was also extrapolated from online resources.  
Discussion  
 Ideally, the most current and up-to-date technologies should be available to all patients 
receiving healthcare. Unfortunately, there are many barriers to providing even the most basic 
healthcare necessities to large groups of people. As aforementioned, research on the preventative 
and screening methods of cervical cancer has increased dramatically in the last 50 years. Because 
of the nature of the disease, it is essential that HPV infections and precancerous lesions are 
identified and treated before they are allowed to progress to cancer. The WHO and the Pan 
American Health Organization (PAHO) have determined the most effective strategies, and have 
created guidelines for optimal practice. However, Central American societies do not always have 
the means to execute them. It is important to take financial, geographical, and cultural matters 
into account to determine the best methods in this part of the world. 
 In the developed world, the HPV vaccine is utilized for prevention, and screenings 
include Pap and/or HPV testing, followed by potential colposcopy, biopsy, or excisional 
procedures. Screening as a whole has been proven to reduce the incidence of cancer, decrease the 
rates of progressive disease, and save lives. While these techniques have been proven successful, 
they are expensive and require trained professionals, high-level equipment, and multiple clinic 
visits.  
Primary prevention with the HPV vaccine is uncommon in most Central American countries. 
Although there are many explanations for low vaccination rates, a prominent issue is simply a 
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lack of public awareness. In 2013, over 600 mothers were interviewed in Honduras, and while 
nearly all of them had been educated about cervical cancer, only 13% had heard of the HPV 
vaccination.24 Despite worldwide support for the vaccine, most health systems do not cover 
vaccination, meaning many patients could not afford to purchase it. Additionally, multiple doses 
are required, which demands multiple visits to a clinic. 
Frequency of visits required is also a considerable obstacle when using Pap tests for 
screening. Screening requirements state that women should be tested every three years, yet the 
necessary equipment if often not available locally. When there are a lack of resources, less 
women receive care. If Pap tests cannot reach populations at the highest risk of developing 
cancer, such as those in rural areas, there is little chance of positive change. Countries able to 
screen 50-70% of women with a Pap test every 3-5 years have death rates of 4 in 100,000 
women, whereas countries with more than 70% coverage see less than 2 in 100,000 deaths per 
year.23 Even when screening is completed, lack of training or education in clinicians commonly 
results in inadequate samples or interpretation. 
 HPV DNA testing is one of the most accurate screening methods, but comes with 
considerable financial cost. In comparison to Pap tests alone, HPV co-testing would be more 
efficient than cytology alone in less developed countries. Co-testing can allow patients to 
decrease the time interval between screenings to five years rather than three.  
In interviews, both residents and medical providers in Costa Rica recognized cervical cancer 
as a prevalent problem for women. Pap screening was the most commonly used diagnostic test 
for providers in both urban and rural areas. Even in Boruca, a small rural community in Costa 
Rica, there were informative infographics and notices for screening with pap tests (Figure 1). Pap 
test frequency recommendations were consistent with the WHO recommendations in these 
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communities. While screening was seen to be very prevalent across the country, preventative 
HPV vaccinations were absent from the required schedules (Figure 2). In regards to more 
advanced cancer care, it was stated that access to colposcopy and further treatment is not easily 
accessible. Many patients do not receive care due to the geographical distance to these facilities.  
Even without these measures widely available, death rates in Costa Rica remain 
significantly lower than in other Central American countries such as El Salvador. The main 
reason for Costa Rica’s comparative success is the funding available for universal healthcare. In 
1974, Costa Rica implemented a social security program—the Caja Costarricense de Seguro 
Social (CCSS or Caja)—with the medical services offered by the Ministry of Health.25 The 
single-payer model is funded by employers, employees, and the government. Using this method, 
nearly 90% of the population has access to quality care.25 Unfortunately, other Central American 
countries do not have the financial stability to put such a program in motion. As a result, the 
quality of healthcare and access for patients is inadequate.  
In order to reduce the incidence and mortality rate of cervical cancer in all Central 
American countries, there are options to assist with outreach and access. For example, in 2003 
Dr. Sanjeev Arora created Extension for Community Healthcare Outcomes (ECHO®). It has 
been implemented to improve cancer care by connecting providers in high resource areas with 
providers in lower resource areas. It is a low cost intervention that allows healthcare 
professionals to “telementor” in order to share knowledge, guidance, and feedback.18 The project 
has been introduced in twelve regions of Central and South America regarding cervical 
dysplasia. In this way, healthcare providers can become confident and skilled to provide 
screening cares in their own communities. Higher numbers of properly trained clinicians equates 
to increased patient care throughout the country.  
Cervical Cancer 16 
 
 
In addition to the ECHO® educational outreach, there are training programs such as the 
Central America Gynecologic Oncology Education Program (CONEP). Volunteer gynecologic 
oncologists travel to Latin America to provide instruction on hands-on screening and treatment 
methods.26 While these types of programs are invaluable, it is important to recognize the need for 
consistency and follow up to ensure the continuity of education.  
It is also important to address the cost of services. Patients living in low-income, rural 
areas are extremely unlikely to seek care if it is unaffordable. Currently, PAHO and the Global 
Alliance for Vaccines and Immunizations (GAVI) financially supports HPV vaccines at a 
discounted price.23 With government or organizational assistance from programs in each 
individual country, vaccines could be made affordable or free of cost to the general public. In 
terms of administration, many countries have found success in school-based vaccination 
programs. This would help to cover nearly all young girls, particularly rural girls who might not 
otherwise have access to healthcare.  
 When considering access to secondary prevention measures, adult women also have 
difficulty finding access to frequent care. It has been suggested that mobile HPV screening 
programs could help bridge the gap in access to care, but this would require a great deal of 
planning and support. It is unclear whether these programs would be able to employ enough 
well-trained staff to make a difference. Some countries around the world have also attempted to 
introduce HPV testing in the form of self-collection, aiming to decrease stigma and increase 
participation. While this may be true, the testing itself is still a costly option. Furthermore, if 
HPV testing is administered without cytology, 15% of invasive cancers can be missed.23  
 Financial burden on both systems and patients is also a large concern for both systems 
and patients. VIA is already commonly used in low-resource settings due to its low cost, 
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simplicity, and acceptance. One study found that VIA costs $3,198 per case in comparison to 
$36,802 with cytologic screening.27 Given the financial constraints of many Central American 
countries, this method is likely a leading approach to decrease cervical cancer incidence.  
Conclusion 
 Ultimately, cervical cancer is a preventable disease with many opportunities to diagnose 
and treat lesions before malignancy occurs. In developed countries with ample resources, 
prevention and screening programs have decreased rates of incidence and mortality by at least 
50%.8 However, the majority of countries within Central America have ineffective screening 
programs due to lack of infrastructure and healthcare resources. Therefore, cervical cancer is one 
of the leading causes of death in women of Central America. 
 HPV vaccinations are not widely administered, but should be a priority for the prevention 
of disease in young girls. In terms of access to care, HPV co-testing with cytology is the most 
accurate method to screen for precancerous and cancerous lesions. However, there are financial 
and geographic challenges in reaching large populations of women in Central America with this 
method.  
There are several strategies that could help to provide both prevention and screening 
measures to the masses of people living in urban and rural Central America. Expanding 
programs such as ECHO® and CONEP can aid in bridging the educational gap. If funding 
assistance can be procured from various worldwide organizations, the HPV vaccine can be 
administered at low costs. The vaccination should be targeted towards young girls prior to the 
onset of sexual activity, ideally in a school-based program.  
In order for these programs to succeed, national recognition from the Ministries of Health 
and governing bodies in Central America are required. Partnerships with health systems across 
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the globe in combination with new initiatives have the potential to increase HPV vaccination 
rates, improve access to services, as well as the quality of screening and treatment.  
Currently, the most effective method in screening for cervical cancer is HPV co-testing 
with cytology. However, with the barriers in low-resource areas in Central America, the best 
option is likely visual inspection by acetic acid (VIA). It is a cost effective, well-recognized 
strategy that requires little training of the clinician. With time and assistance, Central America 
will move towards HPV co-testing, but the central focus should be providing accurate screening 
to as many women in Central America as possible. Early detection and intervention could save 
countless lives.  
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Appendices 
Appendix A: 
Interview Questions 
1. Is the HPV vaccine available at this location? 
2. Is the HPV vaccine commonly given? 
3. Are there any methods currently in place at this location to screen for cervical cancer? If 
so, what are they?  
4. Do you find that the screening methods are effective? 
5. What do you think is the biggest barrier to cancer screening? 
 
Appendix B: Figures 
 
 
 
 
 
 
 
 
 
 
Figure 1: Papanicolau test information displayed in a small clinic in rural Boruca, Costa Rica. 
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Figure 2: Vaccination schedule displayed in a small clinic in rural Boruca, Costa Rica.  
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